stocktrademan
9 years ago
$CNDO DD Notes ~ http://www.ddnotesmaker.com/CNDO
bullish
good price action
$CNDO recent news/filings
## source: finance.yahoo.com
Mon, 24 Nov 2014 18:00:00 GMT ~ Warren Buffett Pick CBI Tumbles On Rating Downgrade
read full: http://www.thestreet.com/story/12965046/1/warren-buffett-pick-cbi-tumbles-on-rating-downgrade.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Fri, 21 Nov 2014 23:02:57 GMT ~ Nasdaq stocks posting largest volume increases
read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-volume-220410239--finance.html
*********************************************************
Sat, 15 Nov 2014 18:04:15 GMT ~ CORONADO BIOSCIENCES INC Financials
read full: http://finance.yahoo.com/q/is?s=cndo
*********************************************************
Tue, 11 Nov 2014 19:06:00 GMT ~ Rackspace Bounces, Making Dan Loeb $34 Million In The Process
read full: http://www.thestreet.com/story/12950056/1/rackspace-bounces-making-dan-loeb-34-million-in-the-process.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Mon, 10 Nov 2014 21:15:51 GMT ~ CORONADO BIOSCIENCES INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exhibit
read full: http://biz.yahoo.com/e/141110/cndo8-k.html
*********************************************************
$CNDO charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CNDO company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CNDO/company-info
Ticker: $CNDO
OTC Market Place: Not Available
CIK code: 0001429260
Company name: Coronado Biosciences, Inc.
Company website: http://www.coronadobiosciences.com
Incorporated In: DE, USA
Business Description: We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.
$CNDO share structure
## source: otcmarkets.com
Market Value: $83,306,923 a/o Nov 21, 2014
Shares Outstanding: 44,312,193 a/o Aug 06, 2014
Float: Not Available
Authorized Shares: 50,000,000 a/o Sep 30, 2011
Par Value: 0.001
$CNDO extra dd links
Company name: Coronado Biosciences, Inc.
Company website: http://www.coronadobiosciences.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CNDO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CNDO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CNDO+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CNDO/news - http://finance.yahoo.com/q/h?s=CNDO+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CNDO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CNDO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CNDO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CNDO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Coronado+Biosciences%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Coronado+Biosciences%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Coronado+Biosciences%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.coronadobiosciences.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.coronadobiosciences.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.coronadobiosciences.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CNDO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001429260&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CNDO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CNDO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CNDO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CNDO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CNDO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CNDO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CNDO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CNDO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CNDO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CNDO+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CNDO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CNDO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CNDO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CNDO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CNDO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CNDO/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CNDO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CNDO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CNDO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CNDO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CNDO
$CNDO DD Notes ~ http://www.ddnotesmaker.com/CNDO
BooDog
10 years ago
Effective January 28, 2014, Dr. Kevin Horgan, our Chief Medical Officer, was separated from service from our Company. On February 20, 2014, our Board named current director, Mr. Weiss, Executive Vice Chairman, Strategic Development. Mr. Weiss has served as a director of our Company since December 19, 2013 and from that time until February 19, 2014 served as the Co-Vice Chairman of our Board.
We do not intend to enter into any employment contract with Mr. Weiss addressing his officer position with our Company. However, in connection with his employment as Executive Vice Chairman, Strategic Development, Mr. Weiss will earn an annual salary of $28,275. In addition, on February 20, 2014, we issued Mr. Weiss 3,958,692 shares of restricted common stock of our Company as an inducement to his employment and for services to be rendered to our Company. The issuance, which was made pursuant to a Restricted Stock Issuance Agreement and under Section 4(2) of the Securities Act of 1933, as amended, provides that 16.67% of the shares will vest on each of the first three annual anniversaries of the date of grant, and 10% of the remainder of the shares will vest upon each closing by our Company of a “Corporate Development Transaction” (as such term is defined in the Restricted Stock Issuance Agreement) provided that if any such Corporate Development Transaction occurs prior to February 20, 2019, vesting of such 10% of the remainder of the shares will occur on February 20, 2019 subject to Mr. Weiss’s continued employment with our Company. The foregoing description of the Restricted Stock Issuance Agreement is qualified in its entirety by reference to the full and complete terms contained in the Restricted Stock Issuance Agreement, which is filed as Exhibit 10.55 to this Current Report on Form 8-K.
Mr. Weiss, age 47, is currently Co-Portfolio Manager and Partner of Opus Point Partners, LLC, which he joined in 2009. He also serves as Executive Chairman, Interim Chief Executive Officer and President of TG Therapeutics, Inc. (NASDAQ: TGTX) since 2011. From 2002 to 2009, Mr. Weiss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), where he helped the company acquire and develop its lead drug Zerenex as well as executed a $100MM+ strategic alliance for Zerenex with JT Tobacco, Inc. and Torii Pharmaceutical Co., Ltd. Mr. Weiss served on the board of directors of National Holdings Corporation (OTD-BB: NHLD) from 2011 to 2012. Mr. Weiss began his professional career as a lawyer with Cravath, Swaine & Moore LLP. He earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. There are no family relationships between Mr. Weiss and any other director or executive officer of our Company.
http://www.sec.gov/Archives/edgar/data/1429260/000114420414011760/v369469_8ka.htm
Not sure if this is part of what's been holding back CNDO.
On February 20, 2014, in connection with the Reporting Person’s becoming the Executive Vice Chairman, Strategic Development of the Issuer, the Issuer and the Reporting Person entered into the Restricted Stock Agreement, pursuant to which the Issuer agreed to issue to the Reporting Person 3,958,692 shares of the Issuer’s Common Stock, subject to specified rights of repurchase in favor of the Issuer should the Reporting Person’s employment with the Issuer end, at a per share price of $2.76. The transaction was effected electronically via the exchange of signatures and documents. Several stockholders of the Issuer, including the Reporting Person, also entered into a Shareholders Agreement on February 20, 2014 (the “Shareholders Agreement”), pursuant to which each such stockholder agreed to vote his shares in favor of electing the individuals proposed for election by the Issuer’s Nominating and Corporate Governance Committee, provided that Mr. Lindsay Rosenwald and the Reporting Person must be on such proposed slate for the provision to be enforced. The parties to the Shareholders Agreement further agreed not to publicly or otherwise advocate for, or encourage in any way, the election of any individual to the Issuer’s board of directors who is not proposed by the Issuer’s Nominating and Corporate Governance Committee.
http://www.sec.gov/Archives/edgar/data/1038977/000114420414012502/sc13d.htm
gotinearly
10 years ago
NEWS--huge...
Form 8-K for CORONADO BIOSCIENCES INC
--------------------------------------------------------------------------------
18-Feb-2014
Entry into a Material Definitive Agreement, Creation of a Direct Financi
Item 1.01 Entry Into a Material Definitive Agreement.
On February 13, 2014, Coronado Biosciences, Inc. (the "Company") executed a Promissory Note (the "Note") in favor of Israel Discount Bank of New York (the "Bank") in the amount of $15.0 million. The Company expects to use proceeds from the Note to repay its prior loan from Hercules Technology Growth Capital, Inc. and fund its general working capital needs. The Company may request revolving advances under the Note in a minimum amount of $100,000 (or the remaining amount of the undrawn balance under the Note if such amount is less than $100,000). All amounts advanced under the Note are due in full at the earlier of: (i) February 13, 2016, or (ii) on the Bank's election following the occurrence and continuation of an event of default. The unpaid principal amount of each advance shall bear interest at a rate per annum equal to the rate payable on the Company's Money Market Account plus a margin of 150 basis points. The Note contains various representations and warranties customary for financings of this type.
The obligations of the Company under the Note are secured by a security interest in, a general lien upon, and a right of set-off against the Company's Money Market Account pursuant to the Assignment and Pledge of Money Market Account, dated as of February 13, 2014 (the "Pledge Agreement"). Pursuant to the Pledge Agreement, the Bank may, after the occurrence and continuation of an event of default under the Note, recover from the Money Market Account all amounts outstanding under the Note. The Pledge Agreement contains various representations, warranties, and covenants customary for pledge agreements of this type.
The Company will default on the Note if, among other things, it fails to pay outstanding principal or interest when due. Following the occurrence of an event of default under the Note, the Bank may: (i) declare the entire outstanding principal balance of the Note, together with all accrued interest and other sums due under the Note, to be immediately due and payable; (ii) exercise its right of set-off against any money, funds, credits or other property of any nature in possession of, under control or custody of, or on deposit with the Bank; (iii) terminate the commitments of the Bank; and (iv) liquidate the Money Market Account to reduce the Company's obligations to the Bank.
The foregoing description of the Note and Pledge Agreement are qualified in their entirety by reference to the full and complete terms contained in the Note and Pledge Agreement which are filed as Exhibits 10.53 and 10.54 to this Current Report on Form 8-K and are incorporated herein by reference.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
ClayTrader
9 years ago
ClarkKant
9 years ago
WealthyKing
10 years ago
Hot Features
Premium
